News the treatment of vaginal microbiota in perimenopausal period

2017 ◽  
pp. 98-102
Author(s):  
Z.M. Dubossarska ◽  

The aim of the research: to evaluate the clinical efficacy and prevention of relapses of inflammatory and degenerative processes of the vagina in patients in perimenopausal period with the drug Femheal. Materials and methods. The study included 40 women aged from 49 to 56 years in perimenopausal period with clinical and laboratory confirmation of nonspecific vulvovaginitis and degenerative processes of the vagina: held pH meter before the appointment of therapy Femheal, 7 days and 3 months after the application Femheal. According to the severity of menopausal disorders to treatment included menopausal hormonal therapy, lipid-lowering and antihypertensive drugs. Results. The use of complex therapy with the use Femheal helps to restore the vaginal microbiota, which is accompanied by disappearance of clinical manifestations nonspecific vulvovaginal (feeling pain in the abdomen, in the genitals, itching, burning, swelling, discomfort and disperion), by normalization of pH. This therapy was effective in the prevention of recurrence, and with an integrated approach to reproductive aging - improving the quality of life. Conclusion. Practicing obstetrician-gynecologists, introducing the pathogenesis of chronic nonspecific vulvovaginal and related violations, especially in a situation when the pathological condition has completely pathognomonic clinical and laboratory evidence, should exclude bacterial vaginosis, sexually transmitted infections, timely identification of changes in the vaginal environment through pH test. Given the high efficiency Femheal in our study and documented in international publications relative to the positive evaluation reattain of action of the drug in the complex treatment of nonspecific vulvovaginitis and prevention of their recurrence, recommended his application for restoration of the vaginal biotope. Key words: nonspecific vulvovaginitis, perimenopausal period, Femheal.

2021 ◽  
Vol 22 (19) ◽  
pp. 10815
Author(s):  
Ellinor Anna Wolf ◽  
Hannah Clara Rettig ◽  
Mariia Lupatsii ◽  
Britta Schlüter ◽  
Kathrin Schäfer ◽  
...  

Sexually transmitted infections (STIs) are a major health concern with clinical manifestations being acknowledged to cause severe reproductive impairment. Research in infectious diseases has been centered around the known major pathogens for decades. However, we have just begun to understand that the microbiota of the female genital tract is of particular importance for disease initiation, infection progression, and pathological outcome. Thus, we are now aware that many poorly described, partially not yet known, or cultured bacteria may pave the way for an infection and/or contribute to disease severity. While sequencing-based methods are an important step in diagnosing STIs, culture-based methods are still the gold-standard method in diagnostic routine, providing the opportunity to distinguish phenotypic traits of bacteria. However, current diagnostic culture routines suffer from several limitations reducing the content of information about vaginal microbiota. A detailed characterization of microbiota-associated factors is needed to assess the impact of single-bacterial isolates from the vaginal community on vaginal health and the containment of STIs. Here we provide current concepts to enable modern culture routines and create new ideas to improve diagnostic approaches with a conjunct usage of bioinformatics. We aim to enable scientists and physicians alike to overcome long-accepted limitations in culturing bacteria of interest to the human health. Eventually, this may improve the quality of culture-based diagnostics, facilitate a research interface, and lead to a broader understanding of the role of vaginal microbiota in reproductive health and STIs.


2017 ◽  
pp. 32-34
Author(s):  
S.A. Vozianov ◽  
◽  
M.P. Zakharash ◽  
Yu.M. Zakharash ◽  
N.A. Sevast'yanova ◽  
...  

The objective: increase the effectiveness of diagnosis and treatment of women with a hyperactive bladder, combined neurogenic pathology of the lower urinary tract and distal colon. Patients and methods. The study included 73 women. In assessing the symptoms of clinical manifestations and EMG and UFS data, two groups of patients were identified: the first group – women with increased tone of the neuro-muscular structures of the hyperkinetic type; the second group - women with an increased tone of the neuromuscular structures of the hypokinetic type. In the first group, 37 women were examined, whose mean age was 44.5±2.3 years, and the duration of the disease was 16.7±1.6 months. The second group included 36 women, whose average age was 43.4±2.1 years, and the average duration of the disease was 19.7±1.5 months. Results. The performed treatment showed clinically high efficiency of electrostimulation application depending on the state of the tone of the neuromuscular structures of the lower urinary tract and the distal part of the large intestine, which is confirmed by the data of UFS and EMG. Conclusion. The obtained data allowed to develop and optimize methods of treatment of women with hyperactive urinary bladder with a combined neurogenic pathology of the lower urinary tract and distal division of the large intestine. Key words: neurogenic disorders in urination, intestine neurogenic dysfunction, detrusor, uroflowmetry, electromyography.


2019 ◽  
Vol 26 (1) ◽  
pp. 175-186
Author(s):  
Vitalii K. Zafiraki ◽  
Alim M. Namitokov ◽  
Elena D. Kosmacheva

Familial hypercholesterolemia (FHC) is a common monogenic disease that occurs with a frequency of ~1:250 and is characterised by a high content of low-density lipoprotein (LDL) in the blood. This disease leads to the early development of atherosclerotic cardiovascular diseases (ACVD). Although the screening and diagnostics issues concerned with FHC are well developed and the modern lipid-lowering therapy can significantly improve the prognosis, the detectability of this disease remains extremely low. In recent years, the concept of FHC has undergone significant changes under the influence of large epidemiological studies, including verification of the FHC diagnosis using genetic tests. The article is aimed at discussing the clinical manifestations of FHC, as well as modern medical and extracorporal approaches to its treatment.Conclusion.Until the advent of modern lipid-lowering drugs, FHC had remained to be a disease with a poor prognosis due to early ACVD and the associated premature death. Today, the diseases is amenable to successful treatment, which, though not eliminating the genetic defect, allows almost the same life duration as in the general population to be achieved. However, all the possibilities of modern approaches to the treatment of this serious disease can be realized provided that a state-level screening program for such patients has been implemented.Conflict of interest: the authors declare no conflict of interest.


Author(s):  
N. Saravanan ◽  
Murugan Swamiappan ◽  
Rajkumar Kannan ◽  
G. Arul Raja

<p class="abstract"><strong>Background:</strong> Sexually transmitted infections (STIs) are the most well established risk factors for the spread of HIV infection. STIs act as cofactors and facilitators for HIV transmission. The effects of HIV infection on immunity can increase susceptibility to other STIs. The aims and objectives of the study were to determine the prevalence of co-infection of sexually transmitted infections among people living with HIV and AIDS.</p><p class="abstract"><strong>Methods:</strong> A retrospective chart review of the data collected from the clinical records of all HIV patients who had attended the STI clinic of Chengalpattu Medical College, Chengalpattu, Tamil Nadu during the five years period, from January 2013 to December 2017, was carried out. Demographic data, clinical manifestations, co-infection of STIs among HIV patients, laboratory investigations and treatment were collected. The data collected were computed and analyzed statistically.<strong></strong></p><p class="abstract"><strong>Results:</strong> During the study period of 5 years from 2013 to 2017 the total number of patients attended the STI clinic were 10825, among that males were 4534 (41.88%) and females were 6291 (58.12%). STIs/RTIs were seen in 2560 (23.65%) cases among the total number of patients attended. HIV was found to be positive in 294 cases, in that 168 (57.15%) were males and 126 (42.85%) were females. In male HIV patients, 51 (30.36%) had co-infection with other STIs/RTIs. In female HIV patients, 57 (45.24) % had co-infection with other STIs/RTIs. Viral STIs was the common co-infection seen in males and vaginal cervical discharge was common in females.</p><p class="abstract"><strong>Conclusions:</strong> STI/RTI co-infection, both symptomatic and asymptomatic are common among PLHIV. Hence they should be regularly counselled regarding the significance of periodic screening for STI/RTIs avoidance of high risk sexual behaviour.</p>


Author(s):  
Valerii Batushkin

Recently, numerous and quite convincing data has been accumulated on the effectiveness and safety of lipid-lowering drugs, beta-blockers, antiplatelet and antihypertensive drugs in patients with chronic heart failure (CHF), depending on the origin of the latter. The practitioner is suggested to use several drugs of different classes at the same time in order to reduce cardiovascular mortality, as well as the risk of recurrent myocardial infarction and ischemic stroke. In CHF, metabolism in cardiomyocytes varies depending on the stage of the disease. The changes that occur in the postinfarction period are compensatory in nature, which contributes to the partial improvement of impaired metabolism, while others, on the contrary, further inhibit the processes of energy production in the myocardium. In our research paper we will discuss some capabilities of metabolic therapy of CHF and prospects in the treatment and prevention using hawthorn extract; analyze the features of interaction of some well-known cardioprotective drugs with long-term antiplatelet therapy in the postinfarction period. Initiation of therapy with a new drug in addition to clopidogrel, such as trimetazidine, may adversely affect antiplatelet activity of clopidogrel (TRACER study, 2019). As a compromise, some herbal cardioprotective drugs may be used. Hawthorn preparations containing vaso- and cardioactive substances have significant potential in the treatment of cardiovascular diseases. Diversified mechanism of action of hawthorn has a significant impact on various parts of the cardiovascular system. Clinical trials of more than 4,000 patients confirm that standardized hawthorn extracts are effective as adjunctive therapy in the treatment of NYHA stage I–III CHF. The main two-year results of the WISO cohort study showed that the three pivotal symptoms of heart failure — fatigue (p = 0.036), stress dyspnea (p = 0.020) and palpitations (p = 0.048) — were significantly less marked after treatment in the hawthorn group versus comparative group. Cochrane analysis (2009) of studies investigating hawthorn extract included 14 studies where hawthorn was used primarily as an adjunct to conventional treatment. Exercise tolerance increased significantly during the treatment with hawthorn extract. Thus, the weighted difference between the average double multiplication rates during cardiac stress test (CST) was 122.76 W/min, whereas end-diastolic pressure in the right ventricle and myocardial oxygen consumption decreased with hawthorn treatment (a weighted mean difference was 19.22 mmHg per 1 min). The reported side effects were infrequent, mild and transient. A special hawthorn extract is indicated for the treatment of patients with NYHA stage II heart failure as an alternative and supplement to the standard evidence-based drug therapy. The beneficial effect on clinical symptoms allowed patients in the Crataegus group to reduce the use of angiotensin-converting enzyme (ACE) inhibitors from 54 to 36% (p = 0.004), cardiac glycosides from 37 to 18% (p = 0.001), diuretics from 61 to 49% (p = 0.061), beta-blockers from 33 to 22% (p = 0.052). At the same time, SPICE and HERB CHF studies show greater efficacy of Crataegus preparations in the treatment of mild to moderate heart failure (NYHA stage I–II). Higher doses (1800 mg) may be required for critically ill patients in order to achieve sustained improvement. Analysis of the data available to date is promising but suggests the need for a more focused approach to dosing based on the disease severity.


Coping is an important component in adapting a person to stressful events and maintaining a psychological balance. The aim of this work was to study the features of coping in patients with cerebrovascular pathology (CVP) in the dynamics of its development at different stages of the disease. At Kharkiv Regional Clinical Hospital - Emergency and Emergency Medicine Center during 2016-2018, observed 383 patients with cerebrovascular pathology on different stage of diseases. The coping assessed by using the Ways of Coping Questionnaire R. Lazarus & S. Folkman. In persons with high risk of CVP, clinical manifestations of CVP and patients after a stroke generally defined more tension of coping than in somatic healthy people. There occurred an imbalance forms of coping with low and high efficiency, dominated confrontation, distancing, avoidance versus problem solving, positive revaluation, increasing the role of social support as external psychosocial resource. Therefore, patients at various stages of CVP had unstable stress coping-profile that was on the one hand the basis for the development of stressrelated psychosomatic changes, on the other – not correctly solve the existing stress. Detection and psychological correction of ineffective coping strategies in patients with CVP is an important component of psychological help for this contingent of patients.


2016 ◽  
Vol 21 (6) ◽  
pp. 329-334
Author(s):  
Sergey L. Kazakovtsev ◽  
T. V Sologub ◽  
V. V Tsvetkov

The use of immunoglobulin preparations for the postexposure prevention of tick-borne encephalitis as the main therapeutic and prophylactic agent fails to have enough high efficiency. For the postexposure prevention and treatment of tick-borne viral encephalitis the use of preparation tioloroin seems to be appropriate. Objective. To determine the expedience of the use of the preparation tiloron for the emergency prevention of tick-borne viral encephalitis and to evaluate its effectiveness in the treatment of patients with febrile and meningeal forms of this infection. Materials and Methods. The evaluation ofpost-exposure prophylaxis of tick-borne was carried out in two groups of individuals (each group was consisted of 100 cases), suffered from the suction of ticks infected by encephalitis virus. Both groups sought for medical help in the first 48 hours after the moment of the tick suction. None of the victims has not been vaccinated against the disease and had no serological markers of infection. According to existing regulations, patients in both groups received post-exposure prophylaxis antiviral tick immunoglobulin in the standard dose. Patients of the second group additionally received an interferon inducer drug tiloron. For the evaluation of the therapeutic efficacy of the drug tiloron there was executed the analysis of clinical and laboratory picture of verified tick-borne viral encephalitis in 40 patients treated at "Republican Hospital for Infectious Diseases" of the city of Syktyvkar in the period from 2010 to 2015. There were studied the dynamics of clinical symptoms, haematological and biochemical markers, CSF, certain immunological indices: CD4, CD8, CD4/CD8, IgM and IgG. For the comparative assessment of the effectiveness of treatment, all the examined patients were divided into 4 groups depending on the clinical diagnosis and ongoing taken causal treatment. Results. Among the patients received post-exposure prophylaxis with inclusion of the preparation tiloron, the disease developed significantly less often, without the formation offocal forms. The use of tiloron in combination therapy reduced the duration of main clinical manifestations in patients with febrile and meningeal forms of the disease, contributed to a more rapid rehabilitation of cerebrospinal fluid, recovery of subpopulations of T-lymphocytes. Conclusions. Immunomodulating inductor tiloron is effective in complex treatment and prevention of tick-borne viral encephalitis.


2019 ◽  
Vol 13 (6) ◽  
pp. 155798831989514 ◽  
Author(s):  
Aleksandra Raczyńska ◽  
Nimmi Nimesha Wickramasuriya ◽  
Anna Kalinowska-Nowak ◽  
Aleksander Garlicki ◽  
Monika Bociąga-Jasik

Since February 2017 in Poland, an increasing number of acute hepatitis A (AHA) cases have been reported; a noteworthy increase to 3,072 cases of AHA in 2017 compared to 35 cases in 2016 was reported by the National Institute of Public Health (NIPH). The aim of this study was to evaluate the demographic features, clinical manifestations, laboratory results, and sexually transmitted coinfections. All cases of AHA diagnosed between February 2017 and February 2018 at the University Hospital in Krakow were analyzed. A total of 119 cases of hepatitis A virus (HAV) were reported; 105 (88%) were males and 14 (12%) were females, with a mean age 31 years (range 19–62). In 84 patients (71%), the HAV was transmitted by oral–anal sexual contact between men. Six women were infected by close house contact with men infected with HAV. The route of transmission was not identified for 29 cases, and 88 patients (74%) required hospitalization. Among the cases, the following coinfections were already diagnosed: HIV 36 patients (30%), chronic hepatitis C virus (HCV) 4 patients (3%), and chronic hepatitis B virus (HBV) 2 patients (1.5%). During AHA diagnosis, some new sexually transmitted infections (STIs) were detected; syphilis eight patients (6.7%), HIV/syphilis seven patients (6%), HIV//HCV/syphilis one patient, and acute retroviral syndrome/ Shigella flexneri one patient. Overall, AHA outbreak in Poland in 2017 affected primarily men who have sex with men (MSM) and was connected with oral–anal sexual contacts, and the majority of patients did not have HAV vaccination. These results show a clear need for routinely offering HAV vaccination to at-risk populations and that awareness among health-care workers about HAV sexual transmission may help introduce prevention methods.


2019 ◽  
Vol 32 (05) ◽  
pp. 358-363 ◽  
Author(s):  
Kyle G. Cologne ◽  
Christine Hsieh

AbstractThis article provides a practical overview for the management of nonviral sexually transmitted diseases affecting the perianal and anorectal regions. Clinical manifestations, diagnosis, and treatment of syphilis, gonorrhea, chancroid, donovanosis, and lymphogranuloma venereum are individually addressed.


Sign in / Sign up

Export Citation Format

Share Document